Abstract
Purpose
To report a case of Vogt–Koyanagi–Harada (VKH) syndrome associated with cutaneous pigmented malignant melanoma (MM) and non-pigmented nodular metastasis after a 10-year recurrence-free interval.
Methods
Case report with long-term follow-up of 11 years. Ocular examinations included best-corrected visual acuity (ETDRS charts), fundus photography, fluorescein angiography, and computer-assisted perimetry. In addition, human leukocyte antigen (HLA) typing was performed.
Results
A 48-year-old white female patient developed VKH disease 5 years after she had undergone surgical treatment of a superficial spreading melanoma on her back in 1991. The first symptoms were diffuse alopecia followed by growth of non-pigmented hair after 8 months. In our clinic, she presented 18 months later with cells and opacification in the vitreous, a macular and optic disc edema and atrophy of the retinal pigment epithelium (RPE). The anterior segment showed endothelial precipitates of the cornea, and a progressive secondary cataract. Fluorescein angiography detected a bilateral edema of the macula and the optic disc, and focal leakage in the RPE level. During follow-up the patient developed more cutaneous signs, such as vitiligo-like depigmentation and poliosis. A non-pigmented lymph node MM metastasis was diagnosed after a 10-year disease-free interval. HLA typing was positive for HLA-A*01, HLA-A*24, HLA-B*08, HLA-B*39, HLA-DRB1*03, and HLADRB1*11.
Conclusion
Our findings suggest that the described ocular findings of VKH disease may represent a component of a syndrome consisting also of melanoma-associated hypopigmentation. Within the framework of current concepts of immunity in patients with MM and VKH , the long recurrence-free interval might support the hypothesis of an autoimmune or hypersensitivity process against melanocytes. The use of immunosuppressive therapy in the treatment of VKH and its potential influence on the development of metastatic disease should be carefully reconsidered.
Similar content being viewed by others
References
Alaez C, del Pilar Mora M, Arellanes L, et al (1999) Strong association of HLA class II sequences in Mexicans with Vogt–Koyanagi–Harada disease. Hum Immunol 60:875–882
Boyd SR, Young S, Lightman S (2001) Immunopathology of the noninfectious posterior and intermediate uveitides. Surv Ophthalmol 46:209–233
Chang MA, Fournier G, Koh HK, Sober AJ, Nakagawa H, Fitzpatrick TB, Albert DM (1986) Ocular abnormalities associated with cutaneous melanoma and vitiligoloke leukoderma. Graefes Arch Clin Exp Ophthalmol 224:529–535
Das PK, van den Wijngaard RM, Wankowicz-Kalinska A, Le Poole IC (2001) A symbiotic concept of autoimmunity and tumor immunity: lessons from vitiligo. Trends Immunol 22:130–136
Kim MH, Seong MC, Kwak NH, et al (2000) Association of HLA with Vogt–Koyanagi–Harada syndrome in Koreans. Am J Ophthalmol 129:173–177
Kuo IC, Rechdouni A, Rao NA, et al (2000) Subretinal fibrosis in patients with Vogt–Koyanagi–Harada disease. Ophthalmology 107:1721–1728
Lertsumitkul S, Whitcup SM, Nussenblatt RB, Chan CC (1999) Subretinal fibrosis and choroidal neovascularization in Vogt–Koyanagi–Harada syndrome. Graefes Arch Clin Exp Ophthalmol 113:1039–1045
Lubin JR, Ni C, Albert DM (1982) Clinicopathological study of the Vogt–Koyanagi–Harada syndrome. Int Ophthalmol Clin 22:141–156
Massi D, Borgognoni L, Franchi A, Martini L, Reali UM, Santucci M (2000) Thick cutaneous melanoma: a reappraisal of prognostoc factors. Melanoma Res 10:153–164
Matsuda H (1970) Electron microscopic studies on Vogt–Koyanagi–Harada syndrome and sympathetic ophthalmia with special reference to the melanocyte. Nippon Ganka Gakkai Zasshi 74:1107–1112
Moorthy RS, Inomata H, Rao NA (1995) Vogt–Koyanagi–Harada syndrome. Surv Ophthalmol 39:265–292
Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9:689–696
Nussenblatt RB, Palestine AG, Whitcup SM, Craven L (1995) Vogt–Koyanagi–Harada syndrome. In: Uveitis: fundamental and clinical practice, 2nd edn. Mosby, St Louis
Ohno S (1981) Immunological aspects of Behcet’s and Vogt–Koyanagi–Harada diseases. Trans Ophthalmol Soc UK 101:335–341
Ohno S, Minakawa R, Matsuda H (1988) Clinical studies of Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 32:334–343
Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742–747
Penn I (1996) Malignant melanoma in organ allograft recipients. Transplantation 61:274–278
Rao NA (1997) Mechanisms of inflammatory response in sympathetic ophthalmia and VKH syndrome. Eye 11:213–216
Rathinam SR, Namperumalsamy P, Nozik RA, Cunningham ET (1999) Vogt–Koyanagi–Harada syndrome after cutaneous injury. Ophthalmology 106:635–638
Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arrellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: Report of an international committee on nomenclature. Am J Ophthalmol 131:647–652
Read RW, Rechodouni A, Butani N, Johnston R, Labree LD, Smith RE, Rao NA (2001) Complications and prognostic factors in Vogt–Koyanagi–Harada disease. Am J Ophthalmol 131:599–606
Rubsamen PE, Gass JD (1991) Vogt–Koyanagi–Harada syndrome. Clinical course, therapy and long-term visual outcome. Arch Ophthalmol 109:682–687
Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R (1997) Predicting ten-year survival of patients with primary cutaneous melanoma: corroboration of a prognostic model. Cancer 80:1426–1431
Sakamoto T, Murata T, Inomata H (1991) Class II major histocompatibility complex on melanocytes of Vogt–Koyanagi–Harada disease. Arch Ophthalmol 109:1270–1274
Sober AJ, Haynes HA (1978) Uveitis, poliosis, hypomelanosis, and alopecia in a patient with malignant melanoma. Arch Dermatol 114:439–441
Sonoda S, Nakao K, Ohba N (1999) Extensive chorioretinal atrophy in Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 43:113–119
Sugiura S (1978) Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol 22:9-35
Zetterstein E, Sagebiel RW, Miller JR, Tallapureddy S, Leong SPL, Kashani-Sabet M (2002) Prognostic factors in patients with thick cutaneous melanoma (>4 mm). Cancer 95:1049–1056
Zhao M, Jiang Y, Abrahams IW (1991) Association of HLA antigens with Vogt–Koyanagi–Harada syndrome in a Han Chinese population. Arch Ophthalmol 109:368–370
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Aisenbrey, S., Lüke, C., Ayertey, H.D. et al. Vogt–Koyanagi–Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Graefe's Arch Clin Exp Ophthalmol 241, 996–999 (2003). https://doi.org/10.1007/s00417-003-0787-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-003-0787-5